MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Lexicon Pharmaceuticals Inc

Închisă

SectorSănătate

1.16 -1.69

Rezumat

Modificarea prețului

24h

Curent

Minim

1.15

Maxim

1.22

Indicatori cheie

By Trading Economics

Venit

8.5M

-25M

Vânzări

-25M

1.3M

Marjă de profit

-2,004.358

Angajați

103

EBITDA

4.1M

-26M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+239.81% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

184M

429M

Deschiderea anterioară

2.85

Închiderea anterioară

1.16

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Lexicon Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 nov. 2024, 12:42 UTC

Principalele dinamici ale pieței

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Comparație

Modificare preț

Lexicon Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

239.81% sus

Prognoză pe 12 luni

Medie 3.67 USD  239.81%

Maxim 6 USD

Minim 1 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLexicon Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.6863 / 0.72Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.